Skip to content
Screener

Ultragenyx Pharmaceutical RARE Total Cost of Revenue

Discontinued — last reported Q2 '19

Total Cost of Revenue at other companies

Eli Lilly logo
Eli LillyLLY
$3.27B+33.5%
Amgen logo
AmgenAMGN
$2.81B-6.6%
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
$2.74M-34.0%
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
$1.53M-87.7%
Moderna logo
ModernaMRNA
$93M-21.8%
Denali Therapeutics Inc. logo
Denali Therapeutics Inc.DNLI
$93K—

Other financials

Income statement

See full
Revenue$214.0M+28.1%
Operating income-$75.0M+30.6%
Net income-$92.0M+20.0%
EPS (diluted)-$0.90+23.1%

Balance sheet

See full
Cash & equivalents$125.0M-29.0%
Total debt$36.0M-10.8%
Total equity-$291.0M-293%
Total assets$1.3B-3.2%

Cash flow

See full
Operating cash flow-$97.0M+11.0%
CapEx$1.0M-66.7%
Free cash flow-$98.0M+12.5%

Valuation

See full
Market cap$2.55B-5.8%
P/S3.6×-0.9×

Profitability

See full
Gross margin97.2%—
Operating margin-73.6%-7.3pp
Net margin-81.7%-4.9pp
FCF margin-68.2%-1.7pp

Returns & leverage

See full
Return on equity-325.6%+36.9pp
Debt / equity3.7×—
Current ratio1.7×-0.7×

Where this comes from

Reported directly by Ultragenyx Pharmaceutical in its filing.

Tagged under the XBRL concept us-gaap:CostOfGoodsAndServicesSold.

The source filing: Ultragenyx Pharmaceutical’s 10-Q, filed August 2, 2019. Open the filing →

Filed
Aug 2, 2019
Fiscal quarter
Q2 FY2019
Calendar quarter
Q2 2019
Accession
0001564590-19-028087

FAQ

What does total cost of revenue mean?
The aggregate of all direct costs attributable to producing goods and delivering services that generated the company's revenue, including materials, labor, and overhead.